Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) disclosed on Wednesday the receipt of the tentative approval from the US Food and Drug Administration for the generic version of Prolensa (bromfenac ophthalmic solution) 0.07% for treating ocular pain in patients.
In conjunction with the US FDA's tentative approval,the company has settled litigation with Bausch & Lomb Inc for Prolensa (bromfenac ophthalmic solution) 0.07%.
According to the company, Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
For the last 12 months, the branded market sales of Prolensa Ophthalmic Solution 0.07% were approximately USD113m, concluded the company.
Amerigen unveils generic bexarotene capsules for US market
FDA Approves Generic Cyclophosphamide for Injection
Lannett awarded US FDA approval for Levofloxacin Oral Solution, with expected imminent launch
Takeda signs relugolix licensing agreement with ASKA
Amneal passes US FDA's approval for Cyclophosphamide for Injection USP
FDA Grants Lannett Approval for Dronabinol Capsules
US FDA approves Lannett's New Drug Application for Dronabinol Capsules USP, 2.5mg, 5mg and 10mg